(NASDAQ: ENTA) Enanta Pharmaceuticals's forecast annual revenue growth rate of 2.05% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Enanta Pharmaceuticals's revenue in 2025 is $64,806,000.On average, 2 Wall Street analysts forecast ENTA's revenue for 2025 to be $1,406,667,333, with the lowest ENTA revenue forecast at $1,391,702,787, and the highest ENTA revenue forecast at $1,421,631,880. On average, 2 Wall Street analysts forecast ENTA's revenue for 2026 to be $1,492,179,025, with the lowest ENTA revenue forecast at $1,453,698,764, and the highest ENTA revenue forecast at $1,530,659,287.
In 2027, ENTA is forecast to generate $1,451,560,972 in revenue, with the lowest revenue forecast at $1,368,187,072 and the highest revenue forecast at $1,534,934,871.